Transient erythroblastopenia of childhood
disease diseaseOn this page
Also known as familial transient erythroblastopenia of childhoodtectransient acquired pure red cell aplasia
Summary
Transient erythroblastopenia of childhood (MONDO:0009197) is a disease. A subtype of primary acquired red cell aplasia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | transient erythroblastopenia of childhood |
| Mondo ID | MONDO:0009197 |
| MeSH | C536980 |
| OMIM | 227050 |
| Orphanet | 98871 |
| NCIT | C131683 |
| SNOMED CT | 191255003 |
| UMLS | C0238478 |
| MedGen | 68670 |
| GARD | 0007793 |
| Is cancer (heuristic) | no |
Also known as: familial transient erythroblastopenia of childhood · tec · transient acquired pure red cell aplasia · transient erythroblastopenia of childhood
Disease family
Classification path: disease › human disease › disease by body system or component › hematologic disorder › anemia › aplastic anemia › acquired aplastic anemia › primary acquired red cell aplasia › transient erythroblastopenia of childhood
Related subtypes (1): adult pure red cell aplasia
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 0.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.